Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.48 (market cap $77.43B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MDLZ | VRTX | |
|---|---|---|
Market Cap | $77.43B | $127.55B |
Volume | 7,695,104 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $557.96 |
52-Week Low | $51.51 | $407.37 |
Typical Hold Time | 107 Days | 120 Days |
Enterprise Value | $97.78B | $121.68B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $59.38, down 0.4% with a bearish technical signal despite beating earnings expectations for three consecutive quarters. The company maintains solid fundamentals with $38.54B revenue, 8.86% net margin, and strong analyst support (76% buy ratings). Recent developments include a dividend increase to $0.52 per share and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling long-term opportunity with attractive valuation metrics (P/E 22.22) and 14% upside to consensus price target of $70.29. Key risks include cocoa cost pressures and competitive snack market dynamics, but the company's global brand strength and consistent execution support bullish outlook for patient investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
